Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Fortunato Morabito; Giovanni Tripepi; Giovanni Del Poeta; Francesca Romana Mauro; Gianluigi Reda; Paolo Sportoletti; Luca Laurenti; Marta Coscia; Yair Herishanu; Sabrina Bossio; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Andrea Visentin; Adalgisa Condoluci; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Francesca Maria Rossi; Antonella Zucchetto; Hamdi Al-Janazreh; Ernesto Vigna; Enrica Antonia Martino; Ramona Cassin; Graziella D′Arrigo; Sara Galimberti; Angela Rago; Ilaria Angeletti; Annalisa Biagi; Ilaria Del Giudice; Riccardo Bomben; Antonino Neri; Gilberto Fronza; Paola Monti; Paola Menichini; Jacopo Olivieri; Giovanna Cutrona; Davide Rossi; Antonio Cuneo; Francesco Di Raimondo; Gianluca Gaidano; Aaron Polliack; Livio Trentin; Robin Foà; Manlio Ferrarini; Valter Gattei; Massimo Gentile

doi:10.1002/ajh.26201

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Fortunato Morabito^*, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria ScortechiniFrancesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Ernesto Vigna, Enrica Antonia Martino, Ramona Cassin, Graziella D′Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Jacopo Olivieri, Giovanna Cutrona, Davide Rossi, Antonio Cuneo, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E269-E272
Journal	American Journal of Hematology
Volume	96
Issue number	8
DOIs	https://doi.org/10.1002/ajh.26201
State	Published - 1 Aug 2021

Access to Document

10.1002/ajh.26201

Cite this

Morabito, F., Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., ... Gentile, M. (2021). Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 96(8), E269-E272. https://doi.org/10.1002/ajh.26201

@article{f0be2f4573b74483b96b151a6582451e,

title = "Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials",

author = "Fortunato Morabito and Giovanni Tripepi and {Del Poeta}, Giovanni and Mauro, {Francesca Romana} and Gianluigi Reda and Paolo Sportoletti and Luca Laurenti and Marta Coscia and Yair Herishanu and Sabrina Bossio and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Andrea Visentin and Adalgisa Condoluci and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Rossi, {Francesca Maria} and Antonella Zucchetto and Hamdi Al-Janazreh and Ernesto Vigna and Martino, {Enrica Antonia} and Ramona Cassin and Graziella D′Arrigo and Sara Galimberti and Angela Rago and Ilaria Angeletti and Annalisa Biagi and {Del Giudice}, Ilaria and Riccardo Bomben and Antonino Neri and Gilberto Fronza and Paola Monti and Paola Menichini and Jacopo Olivieri and Giovanna Cutrona and Davide Rossi and Antonio Cuneo and {Di Raimondo}, Francesco and Gianluca Gaidano and Aaron Polliack and Livio Trentin and Robin Fo{\`a} and Manlio Ferrarini and Valter Gattei and Massimo Gentile",

note = "Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.); AIRC and Fondazione CaRiCal co‐financed Multi‐Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687 (to V.G.) IG‐5506 (to G.F.); Progetto Ricerca Finalizzata PE 2016–02362756 and RF‐2018‐12 365 790 (to A.Z.), Ministero della Salute, Rome, Italy (to V.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198 (to G.G.), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy and RF‐2018‐12 365 790, MoH, Rome, Italy (to G.G.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR‐17‐10 250). Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.); AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.) IG-5506 (to G.F.); Progetto Ricerca Finalizzata PE 2016–02362756 and RF-2018-12 365 790 (to A.Z.), Ministero della Salute, Rome, Italy (to V.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198 (to G.G.), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy and RF-2018-12 365 790, MoH, Rome, Italy (to G.G.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR-17-10 250).",

year = "2021",

month = aug,

day = "1",

doi = "10.1002/ajh.26201",

language = "אנגלית",

volume = "96",

pages = "E269--E272",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "8",

}

Morabito, F, Tripepi, G, Del Poeta, G, Mauro, FR, Reda, G, Sportoletti, P, Laurenti, L, Coscia, M, Herishanu, Y, Bossio, S, Varettoni, M, Murru, R, Chiarenza, A, Visentin, A, Condoluci, A, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Rossi, FM, Zucchetto, A, Al-Janazreh, H, Vigna, E, Martino, EA, Cassin, R, D′Arrigo, G, Galimberti, S, Rago, A, Angeletti, I, Biagi, A, Del Giudice, I, Bomben, R, Neri, A, Fronza, G, Monti, P, Menichini, P, Olivieri, J, Cutrona, G, Rossi, D, Cuneo, A, Di Raimondo, F, Gaidano, G, Polliack, A, Trentin, L, Foà, R, Ferrarini, M, Gattei, V & Gentile, M 2021, 'Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials', American Journal of Hematology, vol. 96, no. 8, pp. E269-E272. https://doi.org/10.1002/ajh.26201

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine : Results of study on 486 cases outside clinical trials. / Morabito, Fortunato; Tripepi, Giovanni; Del Poeta, Giovanni et al.

In: American Journal of Hematology, Vol. 96, No. 8, 01.08.2021, p. E269-E272.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine

T2 - Results of study on 486 cases outside clinical trials

AU - Morabito, Fortunato

AU - Tripepi, Giovanni

AU - Del Poeta, Giovanni

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Sportoletti, Paolo

AU - Laurenti, Luca

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Bossio, Sabrina

AU - Varettoni, Marzia

AU - Murru, Roberta

AU - Chiarenza, Annalisa

AU - Visentin, Andrea

AU - Condoluci, Adalgisa

AU - Moia, Riccardo

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Consoli, Ugo

AU - Scortechini, Ilaria

AU - Rossi, Francesca Maria

AU - Zucchetto, Antonella

AU - Al-Janazreh, Hamdi

AU - Vigna, Ernesto

AU - Martino, Enrica Antonia

AU - Cassin, Ramona

AU - D′Arrigo, Graziella

AU - Galimberti, Sara

AU - Rago, Angela

AU - Angeletti, Ilaria

AU - Biagi, Annalisa

AU - Del Giudice, Ilaria

AU - Bomben, Riccardo

AU - Neri, Antonino

AU - Fronza, Gilberto

AU - Monti, Paola

AU - Menichini, Paola

AU - Olivieri, Jacopo

AU - Cutrona, Giovanna

AU - Rossi, Davide

AU - Cuneo, Antonio

AU - Di Raimondo, Francesco

AU - Gaidano, Gianluca

AU - Polliack, Aaron

AU - Trentin, Livio

AU - Foà, Robin

AU - Ferrarini, Manlio

AU - Gattei, Valter

AU - Gentile, Massimo

N1 - Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.); AIRC and Fondazione CaRiCal co‐financed Multi‐Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687 (to V.G.) IG‐5506 (to G.F.); Progetto Ricerca Finalizzata PE 2016–02362756 and RF‐2018‐12 365 790 (to A.Z.), Ministero della Salute, Rome, Italy (to V.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198 (to G.G.), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy and RF‐2018‐12 365 790, MoH, Rome, Italy (to G.G.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR‐17‐10 250). Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.); AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.) IG-5506 (to G.F.); Progetto Ricerca Finalizzata PE 2016–02362756 and RF-2018-12 365 790 (to A.Z.), Ministero della Salute, Rome, Italy (to V.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198 (to G.G.), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy and RF-2018-12 365 790, MoH, Rome, Italy (to G.G.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR-17-10 250).

PY - 2021/8/1

Y1 - 2021/8/1

UR - http://www.scopus.com/inward/record.url?scp=85105002708&partnerID=8YFLogxK

U2 - 10.1002/ajh.26201

DO - 10.1002/ajh.26201

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 33878220

AN - SCOPUS:85105002708

SN - 0361-8609

VL - 96

SP - E269-E272

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 8

ER -

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Access to Document

Other files and links

Cite this